Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

VDA-1102 studied in new phase II trial for early forms of cutaneous T-cell lymphoma

Feb. 10, 2021

Basilea reports cohort 1 data from phase II study of derazantinib in intrahepatic cholangiocarcinoma

Feb. 10, 2021

Phase III study of napabucasin in metastatic colorectal cancer misses primary endpoints

Feb. 10, 2021

U.S. researchers divulge new immunotherapeutic constructs for cancer

Feb. 10, 2021

Shouyao Holdings (Beijing) identifies new Ret inhibitors

Feb. 10, 2021

Teon Therapeutics patents new adenosine A2A receptor antagonists

Feb. 10, 2021

NSC-765690 and NSC-765599 show antitumor activity against NCI60 human tumor cell lines

Feb. 10, 2021

SorLA identified as a target in anti-HER2-resistant HER2-positive breast cancer

Feb. 10, 2021

European Commission approves Inrebic for newly diagnosed and previously treated myelofibrosis

Feb. 9, 2021

FDA clears Catapult's IND for phase I trial of CAP-100 in CLL

Feb. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...